Supplementary Fig. 1. Viability of (A) Jurkat T-cells and (B) human peripheral blood mononuclear cells (PBMCs) after treatment of three individual compounds (Arochlor-1254, β-hexachlorocyclohexane [HCH], and p,p´-dichlorodiphenyltrichloroethane [DDT]). *P<0.05, **P<0.01, ***P<0.001 compared to the vehicle group.